Patent "Perception": A Contemptuous Natco?
For the longest time, Cipla ranked as our leading poster child for the debate on patents and access to affordable medicines. It took on the multinational drug majors at the drop of a hat and was credited with slashing prices of HIV medications to a small fraction of their prevalent rates. Yusuf Hamied, Cipla’s maverick leader, tellingly notes in a recent interview that: “We had taken the lead to provide affordable medicine for AIDS and I think the time has […]
Patent "Perception": A Contemptuous Natco? Read More »






